Hims & Hers Health (NYSE:HIMS) Shares Down 8.4% - Time to Sell?

Key Points

• Hims & Hers Health shares fell by 8.4%, trading at $49.40 after reaching a low of $50.85, with trading volume significantly down at approximately 10.7 million shares compared to its average of 33 million.
• Analyst ratings have seen mixed opinions, with Citigroup maintaining a "sell" rating while Canaccord Genuity set a price target at $68, reflecting a consensus rating of "Reduce" with a target of $38.92.
• The company reported earnings of $0.17 per share for the latest quarter, missing estimates, but showed a 72.6% increase in revenue year-over-year to $544.83 million.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) fell 8.4% on Tuesday . The company traded as low as $50.85 and last traded at $49.40. Approximately 10,738,311 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 32,973,539 shares. The stock had previously closed at $53.96.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on HIMS shares. Canaccord Genuity Group reissued a "buy" rating and set a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Truist Financial cut their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a report on Monday, August 18th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Zacks Research lowered Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Stock Up 2.7%

The stock has a market capitalization of $13.05 billion, a P/E ratio of 72.18, a price-to-earnings-growth ratio of 3.80 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The stock has a fifty day moving average price of $50.71 and a 200 day moving average price of $45.66.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. During the same period last year, the company posted $0.06 EPS. The business's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,637 shares of the business's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $133,168.50. Following the completion of the transaction, the insider directly owned 166,404 shares in the company, valued at $8,403,402. The trade was a 1.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Chi sold 13,749 shares of the business's stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $694,324.50. Following the transaction, the insider directly owned 297,139 shares of the company's stock, valued at $15,005,519.50. The trade was a 4.42% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,535,085 shares of company stock worth $78,035,921. Company insiders own 13.71% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Invesco Ltd. raised its stake in shares of Hims & Hers Health by 502.2% during the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock worth $127,237,000 after acquiring an additional 2,128,587 shares in the last quarter. Nuveen LLC bought a new position in shares of Hims & Hers Health during the 1st quarter valued at $58,403,000. Clear Street LLC purchased a new position in Hims & Hers Health in the 2nd quarter worth $83,582,000. Norges Bank bought a new stake in Hims & Hers Health in the second quarter worth $78,464,000. Finally, Marex Group plc purchased a new stake in Hims & Hers Health during the second quarter valued at about $53,626,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.